Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2021 | Risk stratification and personalized treatment in HL

Igor Aurer • 7 Jun 2021
ICML 2021
Hodgkin Lymphoma Lymphoma Bleomycin Dacarbazine Doxorubicin Vinblastine

Igor Aurer, MD, PhD, University of Zagreb, Zagreb, Croatia, provides an overview of risk stratification in patients with Hodgkin lymphoma (HL). Prof. Aurer describes criteria outlined by The German Hodgkin Study Group which determines treatment options for patients with favorable and unfavorable HL. Patients with favorable HL are treated with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) and radiotherapy, whereas treatment for unfavorable HL can involve more intensive chemotherapy or less intensive chemotherapy such as ABVD therapy with radiotherapy. This interview took place during the 2021 International Conference on Malignant Lymphoma (16-ICML).

More from Igor Aurer

3:13
Analysis of the EORTC/FIL/LYSA H10 and RAPID trials
Igor Aurer • 7 Jun 2021
2:07
Treating relapse in HL
Igor Aurer • 7 Jun 2021

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals